KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Short-term Investments (2020 - 2025)

Historic Short-term Investments for CRISPR Therapeutics AG (CRSP) over the last 6 years, with Q3 2025 value amounting to $1.6 billion.

  • CRISPR Therapeutics AG's Short-term Investments fell 472.3% to $1.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 billion, marking a year-over-year decrease of 472.3%. This contributed to the annual value of $1.6 billion for FY2024, which is 2310.62% up from last year.
  • According to the latest figures from Q3 2025, CRISPR Therapeutics AG's Short-term Investments is $1.6 billion, which was down 472.3% from $1.5 billion recorded in Q2 2025.
  • Over the past 5 years, CRISPR Therapeutics AG's Short-term Investments peaked at $1.7 billion during Q3 2024, and registered a low of $680.1 million during Q1 2021.
  • For the 5-year period, CRISPR Therapeutics AG's Short-term Investments averaged around $1.4 billion, with its median value being $1.5 billion (2024).
  • Its Short-term Investments has fluctuated over the past 5 years, first skyrocketed by 35161.24% in 2021, then plummeted by 1866.11% in 2023.
  • Over the past 5 years, CRISPR Therapeutics AG's Short-term Investments (Quarter) stood at $1.5 billion in 2021, then grew by 10.12% to $1.6 billion in 2022, then fell by 18.66% to $1.3 billion in 2023, then rose by 23.11% to $1.6 billion in 2024, then grew by 1.47% to $1.6 billion in 2025.
  • Its last three reported values are $1.6 billion in Q3 2025, $1.5 billion for Q2 2025, and $1.6 billion during Q1 2025.